Thursday, 5 December 2013

Peritoneal Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Peritoneal Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Peritoneal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peritoneal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Peritoneal Cancer Global Clinical Trials Review, H2, 2013 report.

Thymus Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Thymus Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Thymus Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Thymus Cancer Global Clinical Trials Review, H2, 2013 report.

Uterine Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Uterine Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Uterine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Uterine Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Uterine Cancer Global Clinical Trials Review, H2, 2013 report.

Vaginal Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Vaginal Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Vaginal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vaginal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Vaginal Cancer Global Clinical Trials Review, H2, 2013 report.

Medical Equipment Monthly Deals Analysis: October 2013 - M&A and Investment Trends

Reportstack has announced a new market report on Medical Equipment Monthly Deals Analysis: October 2013 - M&A and Investment Trends which is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the medical equipment industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the medical equipment industry.

Scope

- Analyze market trends for the medical equipment/medical devices market in the global arena
- Review of deal trends in anesthesia and respiratory devices, cardiovascular devices, dental devices, diabetes care devices, diagnostic imaging, drug delivery devices, endoscopy devices, ENT devices, healthcare IT, hospital supplies, in vitro diagnostics, nephrology and urology devices, neurology devices, opthalmic devices, patient monitoring, surgical equipment, and wound care management segments
- Analysis of M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships in the medical equipment market
- Summary of medical equipment deals globally in the last six months
- Information on the top deals that took place in the medical equipment market
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa
- League Tables of financial advisors in M&A and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs
- Review the financial metrics, such as operating profit ratio, P/E ratio, and EV/EBITDA on mergers and acquisitions

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the medical equipment industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

To view the table of contents and know more details please visit Medical Equipment Monthly Deals Analysis: October 2013 - M&A and Investment Trends report.

MediPoint: Knee Replacement - US Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Knee Replacement - US Analysis and Market Forecasts. The current knee replacement market is a crowded space, with an increasing number of companies offering a myriad of partial, primary/total, and revision prostheses to meet orthopedic surgeons’ demands in the management of knee diseases, primarily osteoarthritis. Worldwide, the primary/total knee segment represents about 80–90% of the entire knee market, with the remainder being partial knee and revision knee. Overall, clinical data show that short- to medium-term survivorship is excellent after almost all common types of knee replacement, regardless of fixation, constraint, and bearing type. Future competition among vendors will be more likely to center on the instrumentation and the ancillary equipment, such as patient-specific instruments, navigation systems, and robotic systems.

The primary factor for growth in the US knee market has been the rise in the aging population and the desire of these patients to maintain a productive lifestyle. This, coupled with constant innovations in implant design and a favorable reimbursement scenario in the US, has led to a continued increase in the procedure volume, despite it being slow and gradual. However, given the current economic situation, patients may choose to postpone their primary joint replacements.

Scope

- An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the US Knee replacement market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for Knee replacement
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Knee replacement sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving the US Knee replacement market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US Knee replacement market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in the US Knee replacement market landscape? Identify, understand and capitalize.

To view the table of contents and know more details please visit MediPoint: Knee Replacement - US Analysis and Market Forecasts report.

Tuesday, 3 December 2013

Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies. 

Roche’s Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck’s PegIntron (peginterferon alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country’s HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug’s inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin). 

Scope
Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Brazil from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Brazil HCV market.

Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for HCV
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Brazil


To view the table of contents and know more details please visit Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022 report. 

Similar Reports: